• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

7.575 -0.965 (-11.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
December 18, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 12, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 10, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
November 06, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 29, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
September 02, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
August 12, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
August 06, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
August 05, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
July 23, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
July 21, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
July 17, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
June 24, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
May 22, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
May 19, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
May 14, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
May 13, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
May 08, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
May 07, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
March 17, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
March 11, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
February 24, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
February 20, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
December 03, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
November 13, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
November 13, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
November 12, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap